some come in seeing a great opportunity - some leave who have made a lot of money.
Q3 earnings picture will be favorable. Early shipments associated with Xembify launching will help top line and reduced legal costs will help bottom line.
The super26 official launch has begun with its higher profit margins. The super26 provides a competitive advantage and saves patients time. Lets see what the market thinks?
The stock uplisting and price appreciation results in a different investor audience. The stock has metamorphosed from a purely penny stock to a stock that is beginning to attract interest from institutions and wealthier investors. The company on some level recognized this and rebranded.
News 
Market Data 
Discover 
